Journal
CLINICAL RESPIRATORY JOURNAL
Volume 7, Issue 3, Pages 281-287Publisher
WILEY-BLACKWELL
DOI: 10.1111/crj.12005
Keywords
asthma; esomeprazole; fundoplication; gastro-oesophageal reflux; hyperresponsiveness; nitric oxide
Categories
Funding
- Tampere University Hospital
- EVO-foundation of Turku University Hospital
- AstraZeneca [10.000 e]
Ask authors/readers for more resources
Introduction Gastro-oesophageal reflux disease (GORD) is suggested to cause or aggravate several respiratory conditions. Studies with proton pump inhibitors have resulted in only minor improvements in pulmonary outcomes in patients with GORD. It has been speculated that operative treatment of GORD might be more efficient as it also diminishes non-acidic reflux. Objectives To compare the effects of esomeprazole 40mg bid and fundoplication on airway responsiveness, forced expiratory volume in 1s (FEV1), exhaled nitric oxide (NO) and respiratory symptoms in patients with moderate-to-severe GORD. Methods Sixty-nine GORD patients had methacholine inhalation challenge performed on them, and FEV1, exhaled NO and respiratory symptoms were measured at baseline, after a 3-month treatment with esomeprazole and 3 months after fundoplication. Primary outcome variable was dose-response slope (DRS), i.e. decline in FEV1 during methacholine challenge divided with the amount of methacholine administered (%/mol). Pre-defined subgroup analysis was performed among those with concomitant asthma (n=12). Results There was no improvement in DRS, FEV1 or exhaled NO after esomeprazole treatment or fundoplication. Cough and dyspnoea measured with visual analog scale improved with esomeprazole treatment (P<0.001), and further after fundoplication (P<0.001). Among those with concomitant asthma, significant improvements in St George Respiratory Questionnaire (SGRQ) scores could be seen after fundoplication. Conclusions Neither esomeprazole treatment nor fundoplication diminishes airway responsiveness or exhaled NO, or improves FEV1 in patients with GORD. Improvements in respiratory symptoms and SGRQ scores after GORD treatments could be detected. However, as this was not a placebo-controlled study, the findings in these secondary endpoints should not be emphasised. ClinicalTrials.cov: NCT00994708.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available